270 related articles for article (PubMed ID: 22266354)
1. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
Brents LK; Gallus-Zawada A; Radominska-Pandya A; Vasiljevik T; Prisinzano TE; Fantegrossi WE; Moran JH; Prather PL
Biochem Pharmacol; 2012 Apr; 83(7):952-61. PubMed ID: 22266354
[TBL] [Abstract][Full Text] [Related]
2. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
Brents LK; Reichard EE; Zimmerman SM; Moran JH; Fantegrossi WE; Prather PL
PLoS One; 2011; 6(7):e21917. PubMed ID: 21755008
[TBL] [Abstract][Full Text] [Related]
3. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
Chimalakonda KC; Seely KA; Bratton SM; Brents LK; Moran CL; Endres GW; James LP; Hollenberg PF; Prather PL; Radominska-Pandya A; Moran JH
Drug Metab Dispos; 2012 Nov; 40(11):2174-84. PubMed ID: 22904561
[TBL] [Abstract][Full Text] [Related]
5. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.
Wiley JL; Lefever TW; Marusich JA; Grabenauer M; Moore KN; Huffman JW; Thomas BF
Neuropharmacology; 2016 Nov; 110(Pt A):143-153. PubMed ID: 27449567
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN
Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483
[TBL] [Abstract][Full Text] [Related]
8. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.
Seely KA; Brents LK; Radominska-Pandya A; Endres GW; Keyes GS; Moran JH; Prather PL
Chem Res Toxicol; 2012 Apr; 25(4):825-7. PubMed ID: 22404317
[TBL] [Abstract][Full Text] [Related]
9. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.
Tai S; Hyatt WS; Gu C; Franks LN; Vasiljevik T; Brents LK; Prather PL; Fantegrossi WE
Pharmacol Res; 2015 Dec; 102():22-32. PubMed ID: 26361728
[TBL] [Abstract][Full Text] [Related]
11. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.
Wiley JL; Marusich JA; Huffman JW
Life Sci; 2014 Feb; 97(1):55-63. PubMed ID: 24071522
[TBL] [Abstract][Full Text] [Related]
12. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
De Luca MA; Castelli MP; Loi B; Porcu A; Martorelli M; Miliano C; Kellett K; Davidson C; Stair JL; Schifano F; Di Chiara G
Neuropharmacology; 2016 Jun; 105():630-638. PubMed ID: 26686391
[TBL] [Abstract][Full Text] [Related]
13. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.
Brents LK; Zimmerman SM; Saffell AR; Prather PL; Fantegrossi WE
J Pharmacol Exp Ther; 2013 Sep; 346(3):350-61. PubMed ID: 23801678
[TBL] [Abstract][Full Text] [Related]
14. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ
Ford BM; Cabanlong CV; Tai S; Franks LN; Penthala NR; Crooks PA; Prather PL; Fantegrossi WE
J Pharmacol Exp Ther; 2019 May; 369(2):259-269. PubMed ID: 30833484
[TBL] [Abstract][Full Text] [Related]
15. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
Hruba L; McMahon LR
J Pharmacol Exp Ther; 2017 Aug; 362(2):278-286. PubMed ID: 28533288
[TBL] [Abstract][Full Text] [Related]
16. Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.
Wiebelhaus JM; Poklis JL; Poklis A; Vann RE; Lichtman AH; Wise LE
Drug Alcohol Depend; 2012 Dec; 126(3):316-23. PubMed ID: 22776442
[TBL] [Abstract][Full Text] [Related]
17. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Canazza I; Ossato A; Trapella C; Fantinati A; De Luca MA; Margiani G; Vincenzi F; Rimondo C; Di Rosa F; Gregori A; Varani K; Borea PA; Serpelloni G; Marti M
Psychopharmacology (Berl); 2016 Oct; 233(21-22):3685-3709. PubMed ID: 27527584
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
19. Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice.
Bilel S; Tirri M; Arfè R; Ossato A; Trapella C; Serpelloni G; Neri M; Fattore L; Marti M
Neurotoxicology; 2020 Jan; 76():17-32. PubMed ID: 31610187
[TBL] [Abstract][Full Text] [Related]
20. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
